Hydrochloorthiazide 1a Pharma (Hydrochlorothiazide)

Hydrochloorthiazide 1a Pharma is indicated for several cardiovascular and renal conditions where reduction of excess fluid or blood pressure is required.

• Hypertension (high blood pressure) management.
• Edema associated with congestive heart failure.
• Edema related to liver cirrhosis.
• Edema due to renal disorders such as nephrotic syndrome.
• Adjunct therapy in combination with other antihypertensive agents.

• Hydrochlorothiazide acts by inhibiting the sodium‑chloride symporter located in the distal convoluted tubule of the nephron. This blockade reduces reabsorption of sodium and chloride, leading to increased urinary excretion of these ions together with water. The resulting diuresis decreases plasma volume, which lowers cardiac output and peripheral vascular resistance, contributing to a reduction in blood pressure.

Like all medications, Hydrochloorthiazide 1a Pharma may cause adverse reactions, which are categorized by frequency and severity.

Common

• Increased urination (polyuria).
• Low blood potassium (hypokalemia).
• Low blood sodium (hyponatremia).
• Elevated blood glucose.
• Dizziness or light‑headedness.

Serious

• Severe electrolyte imbalance (e.g., marked hypokalemia).
• Acute kidney injury.
• Allergic reactions such as rash or angioedema.
• Severe dehydration.
• Blood disorders like leukopenia.

Before initiating therapy, clinicians should evaluate patient history and monitor laboratory parameters to minimize risks.

• Assess renal and hepatic function prior to use.
• Monitor electrolytes, especially potassium and sodium, during treatment.
• Use cautiously in patients with diabetes or gout.
• Avoid in individuals with known hypersensitivity to thiazide diuretics.
• Consider dose adjustment in elderly patients.
• Counsel patients on maintaining adequate fluid intake and reporting severe dizziness.

Hydrochloorthiazide 1a Pharma can interact with other medicines, affecting its efficacy or safety.

Avoid

• Concurrent use with other potent diuretics or lithium, which may increase toxicity.
• Co‑administration with ACE inhibitors or ARBs without monitoring potassium, due to risk of hyperkalemia.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may reduce diuretic effect.

Use with caution

• Antidiabetic agents, as diuretic‑induced hypokalemia can alter glucose control.
• Antihypertensive drugs, requiring blood pressure monitoring to avoid excessive hypotension.
• Corticosteroids, which may enhance sodium loss.